 The outcome of its clinical evaluation has not yet been disclosed.239796-97-5 has improved ADME and MMP-1 selectivity properties and has shown excellent oral efficacy in an animal model of osteoarthritis.Although, the therapeutic objectives for these inhibitors is not cancer, like it has been for most of the MMP inhibitors.